Articles related to ANTIPSYCHOTICS

VMAT2 inhibitors were associated with lower rates of falls, injuries, fractures, and several secondary adverse outcomes than anticholinergic agents in a propensity-matched cohort of adults with tardive dyskinesia.

The FDA approved a supplemental NDA adding randomized withdrawal trial data to the lumateperone label, supporting its role in long-term maintenance and relapse prevention in adults with schizophrenia.

A network meta-analysis of 24 antipsychotics across 78,193 patients with schizophrenia identified clozapine, amisulpride, olanzapine, and risperidone as most effective, with small-to-medium efficacy differences and notable variation in tolerability profiles.

The new chemical entity is an atypical antipsychotic and the active metabolite of iloperidone (Fanapt). Its ability to cross the blood-brain barrier likely contributes to iloperidone’s clinical effects.

“For most patients in the early stages of schizophrenia, symptomatic remission can be achieved using a simple treatment algorithm comprising the sequential administration of amisulpride and clozapine.” — Leucht et al, J Clin Psychiatry 2026

“Health care systems should recruit more trained psychologists and offer combinations of evidence-based pharmacotherapy and psychotherapy to patients with mood disorder, especially with suicide risk in resource-limited settings.” — Study authors, Journal of Psychiatric Research